1. Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Inhibitors

5. Genetic Risk Factors

6. Outstanding Questions for Discussion

7. Type of Factor and Risk for Inhibitors

8. Impact of These Findings on Product Choice

9. Viral Pathogens vs Inhibitors

10. Modifiable Risk Factors

11. Practical Approaches

12. EPIC Trial

13. INHIBIT Trial

14. HIPS Trial

15. Human Cell Line-Derived rFVIII

16. Preclinical Research

17. Nonfactor Replacement Products

18. Nonfactor Replacement Products (cont)

19. Potential Impact of the Nonfactor Replacement Products

20. ITI

21. Research to Optimize ITI

22. The Future

23. Abbreviations